Gilead Ramps Up Cancer Focus With $21 Billion Immunomedics Deal
A technician demonstrates the process of transferring cell samples into a vial at the Gracell Biotechnology Ltd. research laboratory in Shanghai, China. (Photographer: Qilai Shen/Bloomberg)

Gilead Ramps Up Cancer Focus With $21 Billion Immunomedics Deal

(Bloomberg) -- Gilead Sciences Inc. agreed to acquire Immunomedics Inc. for about $21 billion, a substantial premium for the maker of a promising breast-cancer therapy, and another big bet by Gilea...
BQ Install

Bloomberg Quint

Add BloombergQuint App to Home screen.